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Abstract
Background Cancer Anorexia Cachexia Syndrome (CACS) is a distinct atrophy disease negatively inﬂuencing multiple aspects of clinical care and patient quality of life. Although it directly causes 20% of all cancer-related deaths, there are currently no model systems that encompass the entire multifaceted syndrome, nor are there any effective therapeutic
treatments.
Methods A novel model of systemic metastasis was evaluated for the comprehensive CACS (metastasis, skeletal muscle and
adipose tissue wasting, inﬂammation, anorexia, anemia, elevated protein breakdown, hypoalbuminemia, and metabolic derangement) in both males and females. Ex vivo skeletal muscle analysis was utilized to determine ubiquitin proteasome degradation pathway activation. A novel ketone diester (R/S 1,3-Butanediol Acetoacetate Diester) was assessed in multifaceted
catabolic environments to determine anti-atrophy efﬁcacy.
Results Here, we show that the VM-M3 mouse model of systemic metastasis demonstrates a novel, immunocompetent, logistically feasible, repeatable phenotype with progressive tumor growth, spontaneous metastatic spread, and the full multifaceted CACS with sex dimorphisms across tissue wasting. We also demonstrate that the ubiquitin proteasome degradation
pathway was signiﬁcantly upregulated in association with reduced insulin-like growth factor-1/insulin and increased FOXO3a
activation, but not tumor necrosis factor-α-induced nuclear factor-kappa B activation, driving skeletal muscle atrophy. Additionally, we show that R/S 1,3-Butanediol Acetoacetate Diester administration shifted systemic metabolism, attenuated tumor
burden indices, reduced atrophy/catabolism and mitigated comorbid symptoms in both CACS and cancer-independent atrophy
environments.
Conclusions Our ﬁndings suggest the ketone diester attenuates multifactorial CACS skeletal muscle atrophy and
inﬂammation-induced catabolism, demonstrating anti-catabolic effects of ketone bodies in multifactorial atrophy.
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Introduction
Cancer cachexia is a multifactorial atrophy syndrome characterized by skeletal muscle and often adipose tissue wasting
that is typically accompanied by inﬂammation, anorexia, anemia, elevated protein breakdown, hypoalbuminemia, and
metabolic derangement.1–3 Due to its multifaceted nature

and complexity, cachexia is distinct from other forms of
wasting and has been repeatedly shown to worsen prognosis, quality of life, and ability to receive, tolerate, and/or respond to standard of care for cancer patients. Consequently,
20% of cancer-related deaths result from cachexia.3 Unfortunately, the prevalence of cachexia-induced mortality in cancer patients remains unchanged from the initial mortality
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estimations in 1932,4,5 as current modeling systems are limited and therapeutic interventions ineffective.5–7 While the
terminology used to describe cancer cachexia has varied,
cancer cachexia in the presence of comorbid anorexia is associated with higher morbidity and mortality, and is termed
Cancer Anorexia Cachexia Syndrome (CACS).8
Deﬁning the pathology of, and therapeutic response to, cachexia has largely relied on animal model systems6,7; however, no established model comprehensively recapitulates
the multifactorial CACS limiting clinical advancements. Of
note, many model systems do not metastasize signiﬁcantly
despite consistent clinical reports demonstrating a higher incidence of cachexia and its comorbidities in the advanced
metastatic stage.7,9–11 Furthermore, emergent evidence indicates that the metastatic process may contribute to cachexia
onset and progression.12 In fact, it has been recently argued
that the inability to model metastasis may be contributing
to reduced bench to bed side translation.7 The VM-M3
mouse model of systemic metastasis (VM-M3) is a novel syngeneic mouse model derived from a spontaneous glioma
tumor which, when implanted subcutaneously, reliably recreates the spontaneous metastatic process (primary tumor
formation, followed by establishment of distal secondary
tumors), resulting in systemic metastasis to the liver, lungs,
brain, kidneys, and spleen.13,14 Additionally, the model is luciferase tagged, permitting in vivo bioluminescent-based
monitoring of disease progression. This convenient and consistent model system exhibits many of the hallmarks of the
metastatic condition, mirroring important features of clinical
cachexia and addressing the overt gap in current cachexia
modeling systems, yet until now, it has not been analyzed
to determine if it exhibits the comprehensive CACS.
While current models are a critical limitation to clinical advancement, a lack of effective and/or supportive treatments
remains a century old problem.4,5 However, work dating back
a half-century illustrated that patients who underwent
extreme nutrient deprivation produced endogenous metabolites called ketone bodies that accompanied altered systemic
metabolism and skeletal muscle protein kinetics which was
hypothesized to prolong life during catabolic states by
attenuating muscle atrophy.15 Additionally, dietary or
infusion-induced elevations of ketone bodies have been
linked to altered metrics of protein breakdown across various
atrophy and post-absorptive conditions.16–22 These ketone
bodies, which are the end-product of fatty acid oxidation
and subsequent ketogenesis in the hepatic tissue, are
shown to be upregulated during fasting, reduced carbohydrate metabolism, and/or direct intravenous (IV) infusion.
Yet, dietary restriction may be contraindicated in atrophybased disease/environments, and IV infusion is limited to
the clinical/research environment. Recent development of
orally administrated exogenous ketone molecules is
circumventing previous barriers to ketone body elevation
and has led to the rapid expansion of research unveiling

A.P. Koutnik et al.

direct metabolite effects on metabolism, inﬂammation, oxidative stress, and epigenetic regulation, among others.23–26
While our team hypothesized that exogenous ketone bodies
may mitigate inﬂammatory-based atrophy disease,27 their
chronic anti-catabolic effects in multifactorial wasting diseases have remained untested.
The purpose of this study was twofold: (a) to evaluate the
VM-M3 model for the full multifactorial CACS as it is currently
presented in the clinical environment and (b) to determine if
exogenous oral administration of ketone bodies could attenuate atrophy in both the full progressive metastatic CACS
and in a cancer-independent inﬂammation atrophy environment when controlling for confounding and comorbid variables. We hypothesized that the VM-M3 model would more
accurately recapitulate the clinical diagnostic hallmarks of
CACS and that exogenous administration of ketone bodies
would attenuate atrophy in both the cancer and cancerindependent atrophy environments. Our ﬁndings suggest
that the VM-M3 model presents a novel, immunocompetent,
logistically feasible, and repeatable phenotype with progressive tumor growth, spontaneous metastatic spread, and the
full CACS with sex dimorphisms across tissue wasting. This
model addresses three current gaps in CACS modeling: (a)
the progressive spontaneous metastatic environment, (b)
the full clinical syndrome of progressive wasting of skeletal
muscle with altered insulin-like growth factor-1 (IGF-1)/insulin ubiquitin proteasome degradation pathway, adipose tissue
wasting, systemic inﬂammation, anorexia, anemia, hypoalbuminemia, elevated protein breakdown, and metabolic derangement, and (c) sex-speciﬁc temporal cachectic
discrepancies. Additionally, our work demonstrates that oral
administration of R/S 1,3-Butanediol Acetoacetate Diester, a
novel synthetic ketone diester (KDE), supplemented in
addition to a standard diet, was well-tolerated, diminished
anorexia, induced alterations in systemic metabolism, attenuated tumor burden indices, and reduced skeletal muscle atrophy despite circulating anabolic hormones, IGF-1 and insulin,
remaining signiﬁcantly reduced. The current work also demonstrates that the KDE mitigated catabolism in a cancerindependent multifactorial inﬂammation-induced atrophy
environment of lipopolysaccharide (LPS)-induced sepsis, even
when controlling for confounding and comorbid variables.
Taken together, the VM-M3 model has the full progressive
multifactorial CACS, and KDE attenuates multifactorial CACS
and inﬂammatory atrophy.

Methods
Cell Culture
VM-M3 cells were derived from a spontaneous tumor in a
VM/Dk inbred mouse and adapted to cell culture.13 VM-M3
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 973–996
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cells were transduced with a lentivirus vector containing the
ﬁreﬂy luciferase gene under control of the cytomegalovirus
promoter as previously described.13 VM-M3 cells were cultured in D-glucose, L-glutamine, and sodium pyruvate-free
Dulbecco’s modiﬁed Eagle medium (Gibco, Life Technologies)
supplemented with 10% fetal bovine serum (Invitrogen), 25mM D-glucose (Fisher Scientiﬁc), 2-mM L-glutamine (Gibco,
Life Technologies), 1% penicillin-streptomycin (Invitrogen),
and 10-mM HEPES buffer (Gibco, Life Technologies). Cells
were maintained at 37 °C in 95% air, 5% CO2 in a humidiﬁed
incubator.

Animals
Five breeding pairs of the VM/Dk strain of mice were used to
establish and propagate a VM/Dk mouse colony in the University of South Florida (USF) Morsani College of Medicine Vivarium according to standard husbandry protocol. Male and
female VM/Dk mice between 10 and 23 weeks of age were
singly housed to accurately assess individual animal food intake. Bodyweight and food intake were tracked daily prior
to and after social isolation to ensure bodyweight and food
intake normalized prior to cell inoculation (Table S1,
supporting information). Animals were distributed into one
of four groups: sham male (SH-M), sham female (SH-F), cancer male (CA-M), and cancer female (CA-F). Each cancer animal was matched with a sham animal of equivalent sex,
bodyweight, age, and food intake (Figures S1A and S1B) to
ensure appropriate cancer and sex-speciﬁc comparisons. To
determine KDE-induced effects in CACS, VM/Dk animals were
distributed into one of three groups: KDE + VM-M3, VM-M3,
and Sham with equivalent sex, bodyweight, age and food intake at baseline (Figure S6A). One unexplained premature
death occurred in SH-F (Experiment 1a) and Sham (Experiment 4c) groups immediately post-inoculation. To determine
KDE-induced effects post-LPS administration, VM/Dk animals
were distributed into two groups (Figure S7A and S7B): KDE +
LPS and LPS of equivalent bodyweights. All procedures were
approved by the USF Institutional Animal Care and Use Committee (Protocol Numbers R1900 & R5829) and performed
under strict adherence to the NIH Guide for the Care and
Use of Laboratory Animals.

VM-M3 Cell and LPS Implantation
For VM-M3 implantation in the model characterization experiments (Figures 1–5; Figures S1–S5), ~1 × 106 VM-M3 cells
(T. Seyfried, Boston College) in 300-μl sterile PBS (CA-M and
CA-F) or 300-μl sterile PBS only (SH-M and SH-F) were
injected subcutaneously into the left abdominal ﬂank
resulting in primary tumor formation at the injection site
and subsequently systemically metastasizes to most major organs, namely, the liver, kidneys, spleen, lungs, and brain as

previously described.13,14 Additional model analysis revealed
metastatic disease and CACS temporal progression could be
replicated with intraperitoneal administration of VM-M3 cells
(Table S2). This method of implantation further minimized
variability in markers of tumor progression and therefore provides a useful optional method technique in the VM-M3
model for efﬁcient analysis of potential therapeutic agents.
To determine KDE-induced effects on CACS, 1 × 106 VM-M3
cells in 300-μl sterile PBS (KDE + VM-M3 and VM-M3) or
300-μl sterile PBS only (Sham) were administered intraperitoneally (Figure 6; Figure S6). For LPS administration in the septic atrophy model, LPS (Escherichia coli O55:B5; L2880;
Sigma-Aldrich, St. Louis, MO, USA) was diluted in sterile PBS
and administered intraperitoneally at 10 mg/kg as pilot work
indicated a maximal, yet nonfatal, ~15% bodyweight reduction at 10 mg/kg dose.

Survival Analysis
Animal health and behavior were assessed daily. VM-M3
animals were humanely euthanized together with their
sham-matched controls (sex, bodyweight, age, and food intake matched at baseline) by exsanguination under isoﬂurane
(Henry Schein Animal Health, Dublin, OH, USA) according to
Institutional Animal Care and Use Committee guidelines upon
presentation of end of life (EOL) deﬁned criteria associated
with tumor burden and disease progression (decreased
response to stimuli, failure to thrive, labored breathing
and/or locomotion, and/or complete cessation of food
intake). Survival time was recorded.

Tumor Growth and Metastasis
Tumor growth was monitored weekly as a measure of bioluminescence using the Xenogen IVIS Spectrum system (Caliper
LS, Hopkinton, MA, USA). Data acquisition and analysis was
performed using the Living Image® software (Caliper LS). Approximately 15 min prior to in vivo imaging, VM/Dk mice received an intraperitoneal injection of D-Luciferin (50 mg/kg;
88293, Thermo Fisher Scientiﬁc; Waltham, MA, USA). Bioluminescent signal was obtained using the IVIS cooled chargecoupled device (CCD) camera system in both prone and supine positions. As only the cancer cells were transfected with
the luciferase gene, bioluminescent signal (photons/s) of the
whole animal was measured and tracked over time as an indicator of tumor burden and metastatic spread. At EOL, primary tumor, spleen, liver, and adipose tissue were gathered
and saturated with D-Luciferin (10-μl D-Luciferin + PBS/g tissue at 5 mg D-Luciferin/ml PBS dilution) for 5 min and imaged
to determine tumor burden. Ascites ﬂuid was imaged 15 min
after resuspension with D-Luciferin (20-μl D-Luciferin+PBS/ml
ascites ﬂuid at 5 mg D-Luciferin/ml PBS dilution) to assess
presence of circulating tumor cells.
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 973–996
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Body Composition
Bodyweight was assessed daily at the same time (7:00–9:00
a.m.). At EOL, bodyweight and weights of ascites ﬂuid,
primary tumor, calf (combined gastrocnemius & soleus),
anterior thigh (quadriceps), intraperitoneal fat pads, liver,
and spleen tissue were measured (Table S1; Experiment 1a
& b). A follow-up time, course experiment was conducted
at Weeks 1, 2, and 3 to assess weekly changes in bodyweight
and aforementioned tissues for both cancer and shammatched control animals (Experiment 2). For follow up evaluation of KDE in CACS, bodyweight was tracked daily with tissue weight determined at 21 days, prior to EOL (Experiment
4c). All tissue weights were gathered at harvest and normalized to baseline bodyweight (not inﬂuenced by cachexia progression) to allow for appropriate comparison between
animals. For evaluation of KDE in LPS, bodyweight was
tracked daily for evaluation pre- and post-LPS administration
(Experiment 5b & c).

Food Intake and Ketone Diester Administration
Standard diet dry food (2018 Teklad Global 18% protein rodent diet, Harlan) was mixed with deionized water (1 g dry
food/ml deionized water) into a consistent paste and placed
on a 100 × 15-mm dish. Food intake was tracked daily at
the same time (7:00–9:00 a.m.) and replaced every other
day to ensure fresh food. Due to sinusoidal/oscillatory
changes in food intake observed every other day (2-day
pattern), a 4-day (2 × 2-day pattern) average was taken at
EOL and baseline to calculate changes in anorexic symptoms.
KDE was chemically synthesized with physical properties,
preparation, and analysis described in Tables S3–S4. For evaluation of KDE effect on anorexia, food intake was tracked
daily at the same time (7:00–9:00 a.m.). As pilot work indicated reductions in ad libitum food intake with 20–30% by
weight KDE incorporation standard diet, 1%/weight
saccharine (Sigma-Aldrich) and 5%/weight peanut butter
(Natural Jif Creamy, J.M. Smucker Company, Orrville, OH,
USA) were added to paste to increase palatability of standard
diet across groups (Highly Palatable Standard Diet; HPSD). Additional pilot work revealed that incremental incorporation of
KDE from 0% to 30% KDE/weight at 5% KDE/weight/day was
better tolerated and did not result in changes in bodyweight
across time (Figure S6B). Consequently, upon VM-M3 inoculation, KDE + VM-M3 received ad libitum 0% KDE/weight
Day 1, 5% KDE Day 2, 10% KDE Day 3, 15% KDE Day 4, 20%
KDE Day 5, 25% KDE Day 6, and 30% KDE Day 7 through 21
on top of HPSD. VM-M3 and sham received HPSD ad libitum.
As pilot work indicated potential water evaporation in food
paste in ventilated cages, dehydration standard curve was
calculated across various volumes of plated food (5, 10, 25,
50, 100 g per food) with and without KDE over a 2-day period.
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Standard curve equation [water evaporated = 0.2472 (original
grams of water) + 1.364] was used to correct for amount of
dehydration prior to calculating caloric intake. For LPS experiments, 1 × 4 ml/kg KDE gavage or 1 × 4 ml/kg water gavage
were administered for KDE + LPS and LPS only, respectively.
Ab libitum food intake was tracked daily during initial analysis
with caloric restriction reported as the percent reduction in
24-hr caloric intake from pre- to post-LPS administration. Pair
feeding was conducted during subsequent analysis. Pair feeding was accomplished by measuring the 24-hr caloric intake
of LPS-only group and presenting this amount of food to
the KDE + LPS group.

Inﬂammation
Whole blood was gathered at baseline, Week 2, and EOL
prior to anesthetics exposure via submandibular puncture
to prevent anesthetic inﬂuence on inﬂammatory biomarkers28 and to avoid potential ascites contamination
from cardiac puncture. A 60 μl of whole blood was placed
into a K2EDTA tube (BD Microtainer, Franklin, NJ, USA),
relabeled for blinded analysis, and analyzed via HemoTrue
(Heska, Loveland, CO, USA) to assess white blood cell
counts. Remaining whole blood was placed into serum separator tubes (MiniCollect 0.8 ml, Kremsunster, Austria) and
centrifuged (13,000 rpm, 4 °C, 15 min) to isolate serum. A
25 μl of serum was mixed with 25 μl of saline, relabeled
for blinded analysis and analyzed using Bio-Plex (Bio-Rad,
Hercules, CA, USA) ﬂuorescent bead technology to generate
cytokine concentrations via a standard curve (EVE Technology Mouse Cytokine/Chemokine Array 31-Plex). To determine whether spleen or liver enlargement in VM-M3
animals was explained by tumor burden alone or other immunologic factors, tissue bioluminescence was divided by
the difference in tissue weight between VM-M3 and
sham-matched controls. This bioluminescence to tissue
weight ratio for both the liver and spleen was compared
to primary tumor.

Tumor Bioluminescence
• Primary Tumor: Tumor Burden=OrganðmgÞ ¼ Primary
:
Primary Tumor Weight

• Liver: Tumor Burden=ΔOrganðmgÞ ¼ ðCancer BurdenedLiverLiverBioluminescence
WeightSham Liver WeightÞ:
Bioluminescence
• Spleen: Tumor Burden=ΔOrganðmgÞ ¼ ðCancer BurdenedSpleen
Spleen WeightSham Spleen WeightÞ:

Metabolic Biomarkers
Blood glucose and ketone (R β-hydroxybutyrate) concentration were measured using Precision Xtra™ Blood Glucose &
Ketone Monitoring System (Abbott Laboratories, Abbott
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 973–996
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Park, IL, USA). Blood lactate concentration was measured
using Lactate Plus Lactate Meter (Nova Biomedical). IGF-1
and insulin were relabeled for blinded analysis and subsequently analyzed using Luminex 100 system (Luminex, Austin,
TX, USA) with R&D Systems Mouse 1-Plex Luminex Assay
(R&D Systems, Minneapolis, MN, USA) and Milliplex Mouse
Multiplex Kit (Millipore, St. Charles, MO, USA), respectively,
using manufacturer’s protocol.

Clinical Cachexia Biomarker
At EOL, blood was gathered as previously described and red
blood cell count relabeled for blinded analysis via HemoTrue
(Heska, Loveland, CO, USA). Remaining whole blood was centrifuged (13,000 rpm, 4 °C, 15 min) down in serum separator
tubes, relabeled for blinded analysis (MiniCollect 0.8 ml,
Kremsunster, Austria), and analyzed via DRI-CHEM 7000
(Heska) to determine clinical chemistry concentrations.

Muscle Tissue Collection and Processing
Gastrocnemius muscle tissue was immediately gathered,
separated, and ﬂash frozen in liquid nitrogen and stored at
80 °C at harvest. Prior to tissue processing, all tissues were
deidentiﬁed and relabeled for blinded analysis. For protein
and RNA analyses, tissues were removed from 80 °C and
crushed using a liquid nitrogen-cooled mortar and pestle.
For protein analysis, ∼30 mg of powdered tissue was placed
in 1.7-ml microcentrifuge tubes containing 500 μl of ice-cold
cell lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1
mM Na2EDTA, 1 mM EGTA, 1% Triton [Cell Signaling, Danvers,
MA, USA]) pre-stocked with protease and Tyr/Ser/Thr phosphatase inhibitors (2.5 mM sodium pyrophosphate, 1 mM
β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin).
Samples were then homogenized by hand using tight
micropestles; insoluble proteins were removed with centrifugation at 500 g for 5 min and obtained sample lysates were
stored at 80 °C prior to Western blotting and other biochemical assays (described below). For total RNA analysis,
∼15–30 mg of powdered tissue was weighed using an analytical scale with a sensitivity of 0.001 g (Mettler-Toledo;
Columbus, OH, USA). Tissue was then homogenized in 1.7
ml microcentrifuge tubes containing 500 μl of Ribozol
(Ameresco; Solon, OH, USA) via micropestle manipulation
and RNA isolation was performed per manufacturer recommendations. Total RNA concentrations were then determined
in duplicate using a NanoDrop Lite spectrophotometer
(Thermo Fisher Scientiﬁc), and total RNA per unit muscle
weight was used as a surrogate for ribosome density as in
past publications.29,30

Western Blot Analysis
Whole-tissue sample lysates obtained through cell lysis buffer
processing (described above) were batch process-assayed for
total protein content using a BCA Protein Assay Kit (Thermo
Fisher Scientiﬁc). Lysates were then prepared for Western
blotting using 4 × Laemmli buffer at 1 μg/μl. Following
sample preparation, 18 μl samples were loaded onto 4–15%
sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE;
Bio-Rad) and subjected to electrophoresis (180 V for 45–60
min) using premade 1 × SDS-PAGE running buffer (Ameresco;
Framingham, MA, USA) in order of Sham, then Cancer, from
animal number 1 to 12. Proteins were then transferred (200
mA for 2 hr) to polyvinylidene diﬂuoride membranes (BioRad), ponceau-stained and imaged to ensure equal protein
loading between lanes. Membranes were then blocked for 1
hr at room temperature with 5% nonfat milk powder in Trisbuffered saline with 0.1% Tween-20 (TBST; Ameresco). Rabbit
anti-mouse pan nuclear factor-kappa B (NF-κB)/p65 (1:1,000;
cell signaling, catalog #: 8242), rabbit anti-mouse MuRF-1
(1:500; Abcam, Cambridge, MA, USA; catalog #: ab172479),
rabbit anti-mouse Atrogin-1 (1:500; Abcam, catalog #:
ab74023), rabbit anti-mouse Forkhead-box protein O3a
(FOXO3a; 1:500; cell signaling, catalog #: 2497), rabbit antimouse ubiquitin (1:1,000; catalog #: 3933; cell signaling) and
rabbit anti-mouse 20S proteasome core (1:500; Millipore
Sigma, Burlingame, MA, USA; catalog #: ST1053) were incubated with membranes overnight at 4 °C in TBST with 5% bovine serum albumin. The following day, membranes were
incubated with horseradish peroxidase-conjugated anti-rabbit
IgG (1:2,000; cell signaling; catalog #: 7074; Danvers, MA, USA)
in TBST with 5% bovine serum albumin at room temperature
for 1 hr (1:2,000). Membrane development was performed
using an enhanced chemiluminescent reagent [Luminata
Forte Horseradish Peroxidase (HRP) substrate; EMD Millipore,
Billerica, MA, USA], and band densitometry was performed
using a gel documentation system and associated densitometry software (UVP, Upland, CA, USA). Densitometry values for
all targets were divided by whole-lane ponceau densities.
Density/ponceau were divided by the Sham mean and
expressed as relative fold-change relative to the Sham group.

PCR
Two μg of RNA was reverse transcribed into cDNA for RealTime Polymerase Chain Reaction (RT-PCR) analysis with cDNA
synthesis reagents (Quanta Biosciences, Gaithersburg, MD,
USA) per the manufacturer’s recommendations. RT-PCR was
performed using gene-speciﬁc primers and SYBR green chemistry (Quanta Biosciences). Primer sequences used were as
follows: beta-glucuronidase (housekeeping gene, HKG): forward primer 5′-TCAGCTCTGTGACCGATACG-3′, reverse primer
5′- GCCACAGACCACATCACAAC-3′; MyoD: forward primer 5′Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 973–996
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CCTGCCCTCCACATCCTTTT-3′, reverse primer 5′-GAAGGGGGAGAGTGGGGTAT-3′; Atrogin-1/MAFbx: forward primer
5′-CCATCCTCTTTCTTGCCCGT-3′, reverse primer 5′-ATCACTGTCCAACCTGGCTG-3′; MuRF-1: forward primer 5′- TGGGACAGATGAGGAGGAGG-3′, reverse primer 5′- TTTACCCTCTGTGGTCACGC-3′; GPR109a: forward primer 5′-GATGAAAACATCGCCAAGGT-3′, reverse primer 5′-CCTCCAGTCCCAGTTATGGA-3′; IGF-1: forward primer 5′-ACCACCCTGTGACCTCAGTC-3′, reverse primer 5′-CTCCTGGAAACCCAGAACAA-3′.
Melt curve analyses conﬁrmed that only one RT-PCR product
was obtained with each primer set. PCR calculations were
performed as previously described by our team.30 Brieﬂy,
2ΔCq values for each gene of interest at each time point were
calculated whereby ΔCq = gene of interest Cq  geometric
mean housekeeping gene Cq values. All values for a given
mRNA target were then normalized to the Sham mean and
expressed as relative fold-change relative to the Sham group.

20S Proteasome Capacity Assay
Skeletal muscle protein from whole-tissue sample lysates (40
μg) obtained through cell lysis buffer processing (described
above) were batch processed for 20S proteasome activity
using commercially available ﬂuorometric kits (Catalog #:
APT280; Millipore Sigma) as previously described by our laboratory.30 Assay readings are presented as relative ﬂuorometric units normalized to input muscle protein as determined
through the BCA assay described above. The average coefﬁcient of variation for all duplicates was 10.7%.

Statistics
GraphPad Prism 7 software was used for all statistical analysis. Parametric tests were performed for all data sets as all
groups were considered normally distributed. Unpaired or
paired student’s t tests were performed for the comparison
of two groups. One-way ANOVA with Tukey’s multiple comparison post hoc test was performed for more than three
comparisons while Fischer Least Signiﬁcant Difference (LSD)
post hoc was used for three comparisons or less. Results
were considered signiﬁcant when p < 0.05. Robust regression
and outlier removal with coefﬁcient Q = 1% was only used
prior to cytokine analysis as non-physiologic/error values
were independently indicated.31

Results
VM-M3 Presents with Progressive Tumor Growth
and Spontaneous Systemic Metastases
Clinical reports consistently indicate that cachexia is most
prevalent during metastatic disease.5,7,9–11 To determine
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tumor growth rate, metastatic progression, and survival speciﬁc to cancer and sex in the VM-M3 model, CA-M and CA-F
were matched to SH-M and SH-F of equivalent sex,
bodyweight, and age (Figures S1A–S1B). Following implantation of either 1 × 106 VM-M3 cells expressing a luciferase
reporter or PBS vehicle only into VM/Dk mice, tumor
growth, and metastatic spread were tracked weekly. CA-M
and CA-F developed a primary tumor at the implantation
site by Week 1, followed by visible metastatic spread to
various tissues from tumor origin (Figure 1); this was conﬁrmed by ex vivo organ and tissue bioluminescence imaging
(Figures 1C, 1D, 1F, and 1H). Primary tumor weight
increased progressively from Week 1 to EOL (Figure 1G),
with similar metastatic invasion into the liver, spleen,
adipose tissue, and ascites ﬂuid (Figure 1H) between CA-M
and CA-F. This is consistent with the progressive nature of
systemic metastatic disease, where cachexia and comorbidities are most commonly reported in clinical cancer
cachexia.5,7,9–11 Additionally, survival did not differ between
CA-M and CA-F (median: 30 and 28 days, respectively,
Figure 1E; mean: 31.3 ± 1.6 and 32.3 ± 2.4 days, respectively, Figure S1C) illustrating similar tumor burden, metastatic spread, and survival between sexes.

VM-M3 Develops Skeletal Muscle and Adipose
Tissue Wasting Not Represented in Bodyweight
Measurements
Skeletal muscle and adipose tissue atrophy are common
hallmarks of cancer cachexia.1–3 To determine whether the
VM-M3 model had progressive tissue atrophy, bodyweight
was tracked daily during initial analysis and weekly during
subsequent analysis as a superﬁcial marker of body composition (Figure 2A; Table S1). CA-M and CA-F gained signiﬁcantly more bodyweight than Sham groups (Figure 2B);
however, a characteristic feature of the VM-M3 model upon
presentation of widespread metastatic burden is the accumulation of ascites ﬂuid in the intraperitoneal cavity, which
contributes to the elevation in bodyweight. This characteristic is also seen in metastatic patients.32 To address this
concern, ascites ﬂuid was weighed at EOL to determine its
contribution to bodyweight gain. Ascites ﬂuid accounted
for 5.5 ± 1.0 g and 6.3 ± 1.4 g in CA-M and CA-F
bodyweights, respectively (Figure 2C), explaining in part,
along with tumor burden, the elevations in bodyweight seen
in VM-M3 animals.
Clinically, attributing bodyweight changes to skeletal muscle and/or adipose tissue loss can inaccurately represent the
nature of wasting and misguide treatment strategies and
“successes.”33–35 Thus, to directly assess cachexia tissue composition, skeletal muscle, adipose, and tissue weights were
gathered at EOL. Upon conﬁrmation of tissue wasting at
EOL, follow up week-by-week cohort analyses were
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Figure 1 VM-M3 Presents with Progressive Tumor Growth and Spontaneous Systemic Metastases. (A,B) Weekly in vivo IVIS luciferin imaging for
representative animal cancer-female #3 (CA-F3) in the prone and supine positions, respectively. Primary tumor is visible Week 1, subsequent progres2
sive metastases starting Week 2 until end of life (EOL). Red line indicates region of interest (ROI). Color scale/radiance: 3.62e6–1.21e7 photons/s/cm /
sr. Data: Experiment 1a. (C) Ex vivo anterior and posterior view of CA-F3’s organ tissues (liver, spleen, adipose tissue, and primary tumor) via IVIS lu2
ciferin imaging indicates metastatic spread. Red line indicates region of interest (ROI). Color scale/radiance: 1.06e7–1.51e8 photons/s/cm /sr. Data:
EOL, Experiment 1a. (D) Ex vivo ascites ﬂuid IVIS luciferin imaging shows presence of VM-M3 cells. Red line indicates ROI. Color scale/radiance:
2
1.22e6–1.70e6 photons/s/cm /sr. Data: EOL, Experiment 1a. (E) Survival curve for cancer males (CA-M, n = 20) and females (CA-F, n = 18) shows
no signiﬁcant differences. Data: Experiment 1a and b. (F) CA-M (n = 12) and CA-F (n = 12) data points represent the sum of both prone and supine
in vivo bioluminescence for each individual animal. Tumor burden was progressive. Data: Experiment 1a. (G) Primary tumor weight progressively increased in both CA-M (Week 1, n = 4; Week 2, n = 4; Week 3, n = 5; EOL, n = 11) and CA-F (Week 1, n = 4; Week 2, n = 5; Week 3, n = 6; EOL, n =
10) Week 1 to EOL. Primary tumor weight at EOL was signiﬁcantly larger than Weeks 2 and 3 for both CA-M and CA-F. Data: Weeks 1–3, Experiment
2; EOL, Experiment 1a. (H) Whole animal in vivo (n = 12/group) and ex vivo IVIS luciferin imaging (Primary Tumor, CA-M n = 11, CA-F n = 9; liver, spleen,
CA-M n = 12, CA-F n = 12; intraperitoneal adipose tissue, CA-M n = 12, CA-F n = 10; ascites ﬂuid, CA-M n = 7, CA-F n = 5) indicate similar tumor burden.
Data: EOL, whole animal, primary tumor, liver, spleen, and intraperitoneal adipose tissue, Experiment 1a; ascites ﬂuid, Experiment 1b. Data Information: Kaplan-Meier analysis and log-rank test (E). Within group differences across time were analyzed with one-way ANOVA with Tukey’s post hoc (G).
ns
Differences across groups were analyzed with unpaired t test (G,H). Colors (E-G): CA-M, blue; CA-F, red. Data are mean ± SEM. P > 0.05, *P < 0.05.
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Figure 2 VM-M3 Develop Skeletal Muscle and Adipose Tissue Wasting Not Represented in Bodyweight Measurements. (A) Sham males (SH-M, n =
20), cancer males (CA-M, n = 20), sham females (SH-F, n = 17), and cancer females (CA-F, n = 18) bodyweight. Data: Experiment 1a and b. (B) Change in
bodyweight across groups (SH-M, n = 20), (CA-M, n = 20), (SH-F, n = 17), and (CA-F, n = 18). Data: Experiment 1a and b. (C) Ascites ﬂuid weight in CA-M
(5.5 g, n = 8) and CA-F (6.2 g, n = 6). Data: EOL, Experiment 1b. (D) Gastrocnemius and soleus weights as a ratio to baseline bodyweight for SH-M, CA-M
(M, Week 1, n = 4; Week 2, n = 4; Week 3, n = 5; EOL, n = 20), SH-F, CA-F (F, Week 1, n = 5; Week 2, n = 5; Week 3, n = 6; EOL, n = 17). Data: Weeks 1–3,
Experiment 2; EOL, Experiment 1a and b. (E) Quadricep weights as a ratio to baseline bodyweight for SH-M, CA-M (M, Week 1, n = 4; Week 2, n = 4;
Week 3, n = 5; EOL, n = 3), SH-F, CA-F (F, Week 1, n = 5; Week 2, n = 5; Week 3, n = 6; EOL, n = 4). Data: Weeks 1-3, Experiment 2; EOL, Experiment 1b.
(F) Intraperitoneal adipose tissue weights as a ratio to baseline bodyweight tissue weights for SH-M, CA-M (M, Week 1, n = 4; Week 2, n = 4; Week 3, n
= 5; EOL, n = 8), SH-F, CA-F (F, Week 1, n = 5; Week 2, n = 5; Week 3, n = 6; EOL, n = 6). Data: Week 1-3, Experiment 2; EOL, Experiment 1b. Data
Information: Within group differences across time were analyzed with one-way ANOVA with Tukey’s post hoc (D-F). Differences across groups at each
ns
time point were analyzed with unpaired t test (B-F). Colors (D-F): CA-M, blue; CA-F, red. Data are mean ± SEM. P > 0.05, *P < 0.05, **P < 0.01, ***P
< 0.001, ****P < 0.0001.
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 973–996
DOI: 10.1002/jcsm.12554

981

Ketone Bodies Attenuate Wasting in Models of Atrophy

conducted to determine the temporal/progressive nature of
atrophy across tissues and groups. All individual tissues were
set to ratio with baseline bodyweight (so not to be inﬂuenced
by cachexia progression) to allow for appropriate comparison
across groups. CA-M experienced a signiﬁcant decrease in
gastrocnemius and soleus weights starting at Week 2
(12.0%) and extending to EOL (19.5%), compared to SHM (Figure 2D), consistent with the progressive nature of cachectic wasting.1 Similar trends were observed in CA-F, with
decreased gastrocnemius and soleus weights at Week 2
(10.7%; p = 0.09), compared to SH-F (Figure 2E), which were
signiﬁcantly decreased within and across groups at EOL
(20.8%). Quadriceps weight was retained in both CA-M
and CA-F until EOL (Figure 2F), indicating temporal and
tissue-speciﬁc differences in skeletal muscle wasting which
have been observed previously in cachexia models36 and
other clinical atrophy conditions,37 but dissimilar to sexspeciﬁc quadricep atrophy in clinical cachexia.38 CA-M also
presented with progressive decreases in intraperitoneal adipose tissue, with signiﬁcant decreases at Week 3 and EOL
within and across groups (Figure 2F). Discrepantly, CA-F
retained adipose tissue mass up to Week 3, followed by rapid
and complete wasting of adipose tissue between these
timepoints. This altered skeletal muscle and adipose tissue
composition observed in CA-F is consistent with previous
reports in other female cachexia preclinical models39 and
patients,40 but not others,38 and might be explained by
inherent hormonal differences inﬂuencing skeletal muscle41
and adipose tissue.42 The data here serve to conﬁrm tissue
atrophy and sex-speciﬁc cachectic discrepancies in the
VM-M3 model.

VM-M3 Develops Prolonged Systemic
Inﬂammation
Inﬂammation has been reported to drive multiple facets of
the cachexia phenotype, including tissue wasting, anorexia,
metabolic abnormalities, and tumor progression, among
others.3,43 To determine if VM-M3 animals developed systemic inﬂammation, spleen weight, white blood cell count,
and cytokines were measured. Both CA-M and CA-F developed splenomegaly (Figure 3A); however, increased spleen
weight could also be attributed to tumor burden and/or
other immunologic initiators.44 Thus, to determine whether
enlarged spleen weight could be directly attributed to tumor
burden alone, a ratio of tumor burden (bioluminescence in
photon/s) to cancer-induced tissue weight changes (Cancer
to Sham tissue weight differences) was calculated for the primary tumor, liver, and spleen, as the primary tumor bioluminescence would be directly proportional to increased tumor
size and serve as a control ratio. The ratio of tumor burden
to cancer-induced tissue weight differences (Figure 3B) was
similar between the primary tumor and liver, but dissimilar

to spleen, indicating that the change in weight within the liver
could be primarily and/or completely attributed to internal
organ tumor burden. The spleen weight changes, along with
G-CSF elevations (Figure S2B) indicated spleen enlargement
was not due to tumor burden but was indicative of a prominent immunologic response.44,45 Additionally, white blood
cell counts, along with cellular subpopulations (monocytes
and granulocytes), were signiﬁcantly elevated in CA-M
(Figure 3C). In CA-F, however, white blood cell counts were
not signiﬁcantly elevated, although they did show similar
trends to CA-M. Tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, proinﬂammatory cytokines commonly reported
in the cachexia phenotype, were elevated in CA-M and CA-F
across and within groups (Figures 3D and 3E).3,43 However,
IL-1β, another proinﬂammatory cytokine reportedly associated with some cachexia phenotypes, was not signiﬁcantly
altered within or across groups (Figure 3F). These inﬂammatory biomarkers at the organ, cellular, and molecular levels
within VM-M3 animals are indicative of a prolonged systemic
inﬂammatory response and consistent with the cancer
cachexia phenotype.3,43

VM-M3 Develops Anorexia, Anemia, Protein
Breakdown, Hypoalbuminemia, and Metabolic
Derangement
Anorexia, anemia, elevated markers of protein breakdown,
hypoalbuminemia, and metabolic derangement remain
prominent clinical comorbidities of the full CACS,2,9–11,46–50
but are often not evaluated in preclinical modeling to determine the potential clinical relevance of these model systems.
To determine whether the VM-M3 model developed the full
CACS as clinically presented, all aforementioned clinical comorbidities were evaluated. Food intake was monitored daily
to determine the presence of anorexia, a common, contributory, and clinically impactful characteristic of CACS.10,11 Both
CA-M and CA-F developed anorexia, compared to the elevation in food intake seen in both SH-M and SH-F (Figure 4A).
Anemia can be a result of inﬂammation and/or shifted metabolic demands away from red blood cell production,44,51
which can contribute to fatigue and might explain the noticeable lethargy/functional decline in cachexia patients2,46 and
VM-M3 animals. CA-M-developed anemia as indicated by signiﬁcantly reduced hemoglobin, hematocrit, and red blood cell
count (Figure 4B). CA-F had signiﬁcant reductions in red blood
cell count and trends for decreases in hemoglobin. Blood
urea nitrogen and total protein, clinical markers of wholebody protein kinetics, are commonly elevated and decreased,
respectively, in CACS patients.2 CA-M and CA-F had signiﬁcantly elevated blood urea nitrogen levels (Figure 4B). CA-M
and CA-F had signiﬁcantly and non-signiﬁcantly reduced total
protein levels, respectively. Both biomarkers illustrated
increased systemic protein breakdown. Albumin, another
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Figure 3 VM-M3 Develop Prolonged Systemic Inﬂammation. (A) Spleen weights as a ratio to baseline bodyweight for sham males (SH-M), cancer
males (CA-M) [M, Week 1, n = 4; Week 2, n = 4; Week 3, n = 5; end of life (EOL), n = 20], sham females (SH-F), and cancer females (CA-F) (F, Week
1, n = 5; Week 2, n = 5; Week 3, n = 6; EOL, n = 17). Data: Weeks 1–3, Experiment 2; EOL, Experiment, 1a and b. (B) Primary tumor (n = 20), liver
(n = 24), and spleen (n = 24) weight change to bioluminescence ratio via IVIS luciferin imaging. Data: EOL, Experiment 1a. (C) White blood cell count
analysis via impedance analysis (SH-M, n = 9; SH-F, n = 10; CA-M, n = 9; CA-F, n = 10). Data: EOL, Experiment 1a and b. (D-F) Cytokines quantiﬁcation via
Luminex ﬂuorophore intensity analysis (n = 9–12/group/time point). Data: Experiment 1a. Data Information: Within and across group differences were
analyzed with one-way ANOVA with Tukey’s post hoc with >3 comparisons (A) and Fischer LSD post-hoc for ≤3 comparisons (B,D-F). Differences across
groups (A,D-F) or within sexes (C) at each time point were analyzed with unpaired t test. Prior to ANOVA cytokine analysis, robust regression and outlier removal (ROUT) with coefﬁcient Q = 1% was used as non-physiologic/error values were detected (D-F). Colors (A,D-F): CA-M, blue; CA-F, red. Data
are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 4 VM-M3 Develop Anorexia, Anemia, Protein Breakdown, Hypoalbuminemia, and Metabolic Derangement. (A) Food Intake was tracked with
4-day average analyzed at end of life (EOL) to baseline (n = 12/group). Data: Experiment 1. (B) Hemoglobin (n = 10/group), Hematocrit (males n = 10/
group; females n = 9/group), and red blood cell count (n = 10/group) were quantiﬁed with impedance analysis. Blood urea nitrogen (n = 5/group), total
protein (males n = 9/group; females n = 5–6/group), and albumin (males n = 5/group; females n = 6/group) were analyzed via colorimetry analysis.
Data: EOL, Experiment 1a and b. (C) Blood glucose, ketones, and lactate were quantiﬁed via enzyme interaction (n = 8–12/group). Data: blood glucose
and ketones, Experiment 1a; blood lactate, Experiment 3. Data Information: Within group differences across time were analyzed with one-way ANOVA
with Tukey’s post hoc with >3 comparisons (C). Differences across groups (A,C) or within sexes (B) at each time point were analyzed with unpaired t
test. Abbreviations: SH-M, sham males; CA-M, cancer males; SH-F, sham females; CA-F, cancer females. Colors (C): CA-M, blue; CA-F, red. Data are
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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critical biomarker commonly reduced in CACS patients, was
decreased in VM-M3 animals (Figure 4B). This decrease is
hypothesized to be a consequence of shunting of hepatic
resources towards acute response proteins during the inﬂammatory response in CACS2,46 and/or nutritional status52 and
has been linked to higher mortality in cancer, cachexia, and
other atrophy diseases.46,52,53 CA-M and CA-F also developed
hypocholesterolemia, without changes in circulating triglycerides or lipase, potentially attributed to inﬂammation,54 disease progression, and splenomegaly55 (Figure S3).
Blood glucose, R β-hydroxybutyrate, and lactate were also
measured weekly to further evaluate metabolic alterations
associated with the model. Blood glucose did not change, except for a signiﬁcant decrease from baseline to Week 1 in CAM (Figure 4C); however, this did not exclude the possibility
that metabolic changes were occurring while the serum metabolites remained within the homeostatic range, as elevated
glucose turnover has been reported in cachexia patients.47,48,50 Blood R β-hydroxybutyrate did not differ significantly between Sham and Cancer groups for male and
female mice, except for Week 3 for males and Week 1 for females. While limited female cohort availability did not allow
for assessment across both sexes, follow-up analysis indicated that blood lactate was signiﬁcantly elevated in CA-M
(Figure 4C), indicating that metabolic alterations were present likely via the aerobic fermentation pathway (systemically
and/or tumor driven) that may have contributed to increased
metabolic inefﬁciency.47,49,50 Collectively, these observations
in circulating biomarkers were not explained by altered hydration status (Figure S4). Taken together, VM-M3 animals
demonstrated comorbid anorexia, anemia, elevated markers
of protein breakdown, hypoalbuminemia, and metabolic derangement, modeling the comprehensive CACS as clinically
described.

IGF-1/Insulin-FOXO3a-Ubiquitin Proteasome
Pathway is Activated in VM-M3 Skeletal Muscle
Multiple cachexia atrophy mechanisms have been identiﬁed
in rodent modeling and emergent evidence indicates that
the ubiquitin proteasome degradation pathway is a prominent contributor to skeletal muscle atrophy.3,56,57 To determine the mechanism of skeletal muscle atrophy in the VMM3 model of CACS, follow-up analyses were conducted in
CA-M, and activation status of the ubiquitin proteasome
pathway was examined. Results conﬁrmed muscle protein
poly-ubiquitination activation (Figure 5A; Figure S5D), a critical step in the irreversible process of protein degradation.58
Speciﬁcally, 26S proteasome quantity and capacity were
quantiﬁed via 20S proteasome core western blotting and
ﬂuorescence LLYT peptide quantitation of muscle tissue
lysates, respectively. Neither quantity (Figures 5B; Figure
S5E) nor capacity (Figure 5B) of the 26S proteasome were
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altered, indicating atrophy likely occurred via upregulation
of muscle protein poly-ubiquitination.
TNF-α has also been shown to play a direct role in skeletal
muscle atrophy by upregulating NF-κB and subsequently
ubiquitin proteasome activity.59,60 Following prior conﬁrmation of TNF-α elevation (Figure 3D), NF-κB activation was
explored in VM-M3 skeletal muscle to determine which upstream pathway was associated with ubiquitination. Nuclear
fraction versus total NF-κB (65 kDa) protein analysis revealed
no signiﬁcant differences between CA-M and SH-M (Figure 5C;
Figures S5F and S5G); however, NF-κB is temporally
regulated, and analysis may have missed the activation
timepoint.61 Thus, mRNA expression of MyoD, MuRF-1,
Atrogin-1, and GRP109a as well as protein levels of MuRF-1
and Atrogin-1 were analyzed as surrogates of NF-κB activation. MyoD expression drives myogenesis in skeletal muscle,
but activation of NF-κB is known to directly induce the degradation of MyoD mRNA.62 Results indicated MyoD mRNA was
unchanged in CA-M (Figure 5D). Additionally, MuRF-1 and
Atrogin-1 are skeletal muscle-speciﬁc E3 ligases which can
be upregulated via NF-κB activation; however, both mRNA
and protein levels were similar between conditions
(Figures 5E and 5F; Figure S5H and S5I). mRNA levels for
GPR109a, a receptor protein known to be upregulated by
NF-κB activation and subsequently induce negative feedback
upon NF-κB pathway activation,63,64 revealed no differences
between conditions either (Figure S5A). Interestingly, total
RNA levels (a surrogate of ribosome density) and nuclear fraction protein levels were signiﬁcantly reduced in the VM-M3
skeletal muscle (Figures S5B and S5C) further suggesting
these animals were in a catabolic state. TNF-α is known to
chronically activate NF-κB. Given that all of the aforementioned markers indicated no differences between conditions
regarding NF-κB pathway activity, serum levels of a reported
counter-regulator of TNF-α-induced NF-κB activation in muscle, IL-10, was explored.65 Serum IL-10 was elevated, potentially explaining our NF-κB results (Figure 5G) despite the
increases in TNF-α (Figure 3D) and poly-ubiquitinated protein
levels (Figure 5A).
Another upstream activator of the ubiquitin proteasome
pathway is via IGF-1/insulin, FOXO3a, and Atrogin-1 signaling.56,66 Serum IGF-1 and insulin levels were analyzed in
VM-M3 animals to determine if this upstream mechanism
was associated with muscle protein poly-ubiquitination.
Quantiﬁcation of serum IGF-1 and insulin revealed 26-fold
and 4.6-fold downregulation of both anabolic hormones,
respectively (Figure 5H). Quantiﬁcation of nuclear fraction
FOXO3a revealed a 2.3-fold increase in VM-M3 animals
(Figure 5I). Collectively, these results suggest that VM-M3
skeletal muscle atrophy may occur through a reduction in
serum IGF-1/insulin and a subsequent increase in FOXO3a
activation resulting in an increase in muscle protein
poly-ubiquitination; all of which was independent of TNF-αinduced NF-κB activation.
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Figure 5 IGF-1/Insulin-FOXO3a-Ubiquitin Proteasome Pathway is Activated in VM-M3 Skeletal Muscle. (A) Immunoblotting and quantitative densitometry analysis indicated poly-ubiquitination was signiﬁcantly increased in CA-M compared to SH-M (n = 12). Data: Gastrocnemius, EOL, Experiment
1a. (B) Immunoblotting and quantitative densitometry analysis indicated 20S proteasome core was not changed in CA-M compared to SH-M (n = 12/
group). Fluorometric enzymatic assay indicated no change in 20S proteasome capacity (n = 12/group). Data: Gastrocnemius, EOL, Experiment 1a. (C)
Immunoblotting total and nuclear fraction NF-κB (65 kDa) and ponceau staining. Densitometry quantiﬁcation did not indicate altered NF-κB activation
between SH-M (n = 11) and CA-M (n = 12). Data: Gastrocnemius, EOL, Experiment 1a. (D) RT-qPCR analysis of mRNA MyoD in SH-M and CA-M revealed
no differences (n = 12/group). Data: Gastrocnemius, EOL, Experiment 1a. (E) RT-qPCR analysis of mRNA MuRF-1, immunoblotting and quantitative densitometry analysis of MuRF-1 in SH-M and CA-M revealed no differences (n = 12/group). Data: Gastrocnemius, EOL, Experiment 1a. (F) RT-qPCR analysis
of mRNA Atrogin-1, immunoblotting and quantitative densitometry analysis of Atrogin-1 in SH-M and CA-M revealed non-signiﬁcant elevations (n = 12/
group). Data: Gastrocnemius, EOL, Experiment 1a. (G) Cytokines quantiﬁcation via Luminex ﬂuorophore intensity analysis (n = 7–9/group) indicate elevations in IL-10. Data: Experiment 1a. (H) Serum hormone levels quantiﬁed via Luminex xMAP ﬂuorophore intensity analysis demonstrated 26-fold
reduction in insulin-like growth factor-1 (IGF-1) and 4.5-fold reduction in Insulin in CA-M compared to SH-M (n = 11/group). Data: Week 3, Experiment
4c. (I) Immunoblotting and quantitative densitometry analysis indicated nuclear fraction FOXO3a was signiﬁcantly increased (2.4-fold) in CA-M (n = 12)
compared to SH-M (n = 11). Data: Gastrocnemius, EOL, Experiment 1a. Data Information: Within group differences across time were analyzed with
one-way ANOVA with Fischer LSD post hoc for ≤3 comparisons (G). Differences across groups at each time point were analyzed with unpaired t test
(A-I). Prior to ANOVA cytokine analysis, robust regression and outlier removal (ROUT) with coefﬁcient Q = 1% was used as non-physiologic/error values
ns
were detected (G). Colors (G): CA-M, blue. Data are mean ± SEM. P > 0.05, **P < 0.01, ****P < 0.0001.
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Ketone Diester Mitigates Comorbidities, Tumor
Burden, and Skeletal Muscle Atrophy in Cancer
Anorexia Cachexia Syndrome
Existing evidence implicates IGF-1/insulin, FOXO3a, and the
ubiquitin proteasome pathway in muscle homeostasis and
numerous atrophy conditions,56,57 including nutrient deprivation.66,67 Interestingly, patients undergoing extreme nutrient
deprivation (i.e., prolonged fasting/anorexia) upregulate endogenous ketone body production, which is hypothesized to
allow for prolonged survival via a protective and progressive
metabolic adaptation that attenuates muscle atrophy.15,16
Previously, dietary restrictions and/or infusion-induced elevations of ketone bodies limited the exploration and clinical
translation of therapeutic ketosis; however, a novel, orally ingestible exogenous KDE may be a viable therapeutic strategy.
This KDE was assessed to determine its effect on anorexia,
systemic metabolism, tumor and metastatic burden, and skeletal muscle catabolism in multifactorial CACS modeling.
To determine whether KDE could alter systemic metabolism, blood metabolites were measured at baseline following
a standard diet and after a 4 day transition to a standard diet
supplemented with 20% KDE, 25% KDE, or 30% KDE. Results
indicated 20% KDE and 30% KDE caused signiﬁcant elevations
in blood ketone levels, with 30% KDE inducing the highest
ketone elevations (Figure S6C). All KDE groups exhibited
signiﬁcant reductions in blood glucose levels, with 30% KDE
inducing the greatest reduction in glucose. A second study
was initiated to expand upon these ﬁndings, as prior work revealed that exogenous administration of ketone bodies may
reduce ad libitum food intake68,69 and confound evaluation
of KDE effect on catabolism. To control for this effect, food
palatability was increased by incrementally integrating the
KDE into the diet (5%/day) over a 7-day period to achieve
30% KDE. The 30% KDE was well-tolerated as indicated by
bodyweight maintenance (Figure S6B), and since 30% KDE
caused the greatest alteration in systemic metabolism,
mirroring the metabolic alterations seen during extreme
nutrient deprivation,15 30% KDE was administered in VMM3 CACS (KDE + VM-M3) utilizing intraperitoneal implantation to determine whether KDE would alter the course of
CACS-induced atrophy compared to VM-M3 CACS alone
(VM-M3) and PBS only (Sham). Food intake was tracked daily
to determine if KDE administration altered the anorexic
phenotype. VM-M3 experienced a reduction in food intake
(Figure 6A); however, animals in the KDE + VM-M3 demonstrated attenuation of the predicted anorexic phenotype in
this CACS model (Figure 6A). To determine whether KDE
could alter metabolism in CACS, blood ketones, glucose, and
lactate were measured weekly. KDE induced sustained elevations in circulating ketones and reductions in blood glucose in
KDE + VM-M3 compared to both VM-M3 and Sham
(Figure 6B), illustrating KDE-induced alterations in CACS systemic metabolism. No difference was found between KDE +
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VM-M3 and VM-M3 for blood lactate (Figure 6B), potentially
indicating similar tumor or inﬂammation-induced aerobic
fermentation.70,71 Thus, to determine if KDE altered tumor
burden, in vivo bioluminescence imaging was analyzed
weekly. Interestingly, KDE + VM-M3 demonstrated nonsigniﬁcant reductions in whole animal tumor burden
(Figure 6C). Additionally, ascites ﬂuid, a surrogate marker of
metastatic spread,32 was signiﬁcantly reduced in KDE + VMM3 compared to VM-M3 (Figure 6D), indicating KDE-induced
reductions in markers of tumor burden.
To determine if KDE altered body composition and
whether this was through alteration in model-speciﬁc catabolic drivers, bodyweight was tracked daily, while serum
IGF-1 and insulin as well as relative masses for cardiac tissue,
adipose tissue, and skeletal muscle tissue were evaluated 3
weeks post-implantation, prior to EOL. KDE + VM-M3 had a
lower bodyweight compared to VM-M3 and Sham (Figure 6E);
however, as both ascites ﬂuid and tumor burden confound
bodyweight in VM-M3 animals, bodyweight alone could not
reliably indicate tissue atrophy in the VM-M3 model of CACS.
KDE + VM-M3 and VM-M3 both demonstrated signiﬁcantly
reduced serum IGF-1 and insulin, demonstrating that KDE
did not alter circulating anabolic hormone levels (Figure 6F).
Cardiac tissue was found to be unaltered by CACS or across
groups (Figure 6G). Additionally, adipose tissue atrophied to
equivalent levels in KDE + VM-M3 and VM-M3, indicating
KDE was unable to alter adipose tissue catabolism. However,
the KDE did attenuate muscle atrophy across numerous skeletal muscle tissues (Figure 6I). Taken together, the KDE was
well tolerated, attenuated anorexia, altered systemic metabolism, attenuated indices of tumor burden, and reduced skeletal muscle atrophy without changing circulating IGF-1 and
insulin levels, illustrating a unique and multifaceted anti-CACS
therapy.

Ketone Diester Mitigates Bodyweight Loss and
Comorbidities in Inﬂammation-Induced Atrophy
Reductions in anorexia, tumor burden, and skeletal muscle
atrophy all present ideal outcomes in the clinical environment
of CACS. It should be noted, however, that altered anorexia
and tumor burden can confound interpretation of the direct
effects of the KDE on skeletal muscle atrophy. To determine
direct effects of KDE on catabolism when controlling for confounding variables of cancer and anorexia, KDE was evaluated
in an inﬂammation-induced atrophy environment of LPSinduced sepsis, which has been shown to produce an overlapping multifactorial atrophy environment of low IGF-1/insulin,
systemic inﬂammation, anorexia, anemia, hypoalbuminemia,
metabolic derangement, and upregulated ubiquitin proteasome signaling.2 Due to the rapid nature of LPS-induced
atrophy, various dosages of KDE were gavaged to determine
their ability to rapidly shift systemic metabolism. Both 4
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Figure 6 Ketone Diester Mitigates Comorbidities, Tumor Burden Indices, and Skeletal Muscle Atrophy in Cancer Anorexia Cachexia Syndrome. (A)
Food intake was tracked daily and compared across groups. (n = 3/group; group = cage; 3-4 animals/cage). Data: Experiment 4c. (B) Blood ketones,
glucose, and lactate were quantiﬁed for Ketone Diester + VM-M3 cancer anorexia cachexia syndrome (KDE + VM-M3, n = 12), VM-M3 (n = 12), and
sham (n = 11) via enzyme interaction. KDE + VM-M3 demonstrated shifts in system metabolism. Data: Experiment 4c. (C) KDE + VM-M3 (n = 12)
and VM-M3 (n = 12) data points represent the average of both prone and supine in vivo bioluminescence for each individual animal. KDE + VM-M3
has non-signiﬁcant reductions in tumor burden. Data: Experiment 4c. (D) Ascites ﬂuid weight in KDE + VM-M3 (1.9 g, n = 11), VM-M3 (3.0 g, n =
11), and sham (0 g, n = 11). Data: Week 3, Experiment 4c. (E) Daily bodyweight for KDE + VM-M3 (n = 12), VM-M3 (n = 12), and Sham (n = 11).
VM-M3 and sham saw an increase in bodyweight compared to KDE-VM-M3, starting Day 14. Data: Experiment 4c. (F) Serum hormone levels quantiﬁed
via Luminex ﬂuorophore intensity analysis demonstrated signiﬁcant reductions in insulin-like growth factor-1 (IGF-1) and insulin in KDE-VM-M3 (n = 12)
and VM-M3 (n = 11) compared to SH-M (n = 11). Data: Week 3, Experiment 4c. (G) Cardiac tissue weight set to baseline bodyweight (n = 10/group)
with no signiﬁcant difference across groups. Data: Week 3, Experiment 4c. (H) Intraperitoneal adipose tissue weight set to baseline bodyweight with
signiﬁcant reductions in KDE + VM-M3 and VM-M3 compared sham (n = 10/group). Data: Week 3, Experiment 4c. (I) Gastrocnemius, soleus, quadricep,
tibialis anterior, and hind limb (four muscle pooled analysis) skeletal muscle weights set to baseline bodyweight showed KDE + VM-M3 attenuated
skeletal muscle atrophy across several tissues compared to VM-M3 (n = 10/group). Data: Week 3, Experiment 4c. Data Information: Differences across
groups at each time point were analyzed with one-way ANOVA with Fischer LSD post hoc for ≤3 comparisons (A,B,E-I) or unpaired t test for individual
comparisons (C,D). Colors (A-C,E): KDE + VM-M3, green; VM-M3, blue. Data are mean ± SEM. KDE-VM-M3 versus VM-M3 *P < 0.05, KDE-VM-M3 ver§
¥
ns
sus sham P < 0.05, VM-M3 versus sham P < 0.05 (A,B,E). P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (C,D,F-I).
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ml/kg and 5 ml/kg KDE dosages resulted in signiﬁcant and
rapid reductions in blood glucose and elevations in blood
ketones (Figure 7A). To determine KDE’s effect on
cancer-independent catabolism, a maximal nonfatal LPS dose
(10 mg/kg) was administered, followed by a single 4 ml/kg

A.P. Koutnik et al.

water (LPS) or KDE (KDE + LPS) gavage. KDE attenuated
bodyweight loss 47% within the ﬁrst 24-hr post-LPS
administration (Figure 7B). Consistent with what was found
in CACS, KDE also signiﬁcantly reduced anorexic symptoms
(Figure 7C).

Figure 7 Ketone Diester Mitigates Bodyweight Loss and Comorbidities in Inﬂammation-Induced Atrophy. (A) Blood ketones and glucose were quantiﬁed for ketone diester (KDE) at 2 ml/kg (n = 3), 3 ml/kg (n = 2), 4 ml/kg (n = 3), 5 ml/kg (n = 3) via enzyme interaction. KDE at 4 ml/kg demonstrated
shifts in system metabolism. Data: Experiment 5a. (B) Percentage bodyweight loss 1-day post administration of 10 mg/kg lipopolysaccharide with either 4-ml water (LPS, n = 4) or 4 ml/kg KDE (KDE + LPS, n = 5) gavage. Data: Experiment 5b. (C) Percentage caloric restriction 1-day post LPS (n = 4) or
KDE + LPS (n = 5). Data: Experiment 5b. (D) Percentage bodyweight loss tracked for 13 days following LPS (n = 4) or KDE + LPS (n = 5). Data: Experiment
5b. (E) Time to recovery as time taken to return to baseline bodyweight following LPS (n = 4) or KDE + LPS (n = 5). Data: Experiment 5b. (F) Percentage
bodyweight loss in pair-fed animals 1 day post LPS (n = 4) or KDE + LPS (n = 4). Data: Experiment 5c. Data Information: Within group differences compared to time point “0” were analyzed with one-way ANOVA with Fischer LSD post hoc for ≤3 comparisons (A). Difference across groups were analyzed
unpaired (B-D,F). Differences across time point were analyzed with paired t test (E). Colors (D-E): KDE + LPS, green; LPS, blue. Data are mean ± SEM. 4
§
¥
ns
ml/kg different from time point “0” P < 0.05, 5 ml/kg different from time point “0” P < 0.05 (A). P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001
(B-F).
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Animals were followed over a 13-day period to determine
chronic effects of KDE. KDE signiﬁcantly attenuated chronic
LPS-induced bodyweight loss (Figure 7D). To determine
whether KDE would alter length of recovery time from a maximal nonfatal LPS dose, bodyweight was assessed over the
13-day time period to determine length of time before animals returned to baseline bodyweight. KDE + LPS recovered
within 10 days, while LPS did not recover within the 13-day
time period (Figure 7E). While this illustrates that a single
KDE administration could rapidly alter systemic metabolism
and attenuate catabolism and comorbid symptoms, reducing
anorexia can potentially confound catabolism. To determine
if KDE attenuated catabolism in post-LPS administration when
controlling for anorexia, animals were pair-fed and administered a single 4 ml/kg gavage. Pair-fed KDE + LPS signiﬁcantly
reduced bodyweight loss 28% compared to LPS group (Figure 7F), indicating KDE attenuated catabolism independent
of food intake. Taken together, the KDE attenuated anorexia
and catabolism in a cancer-independent inﬂammatoryatrophy environment when comorbidities were controlled,
suggesting a direct anti-catabolic effect of KDE in these multifactorial catabolic environments.

Discussion
An inability to model the clinically reported environment of
progressive metastatic CACS and discover effective treatments that mitigate both muscle atrophy and comorbid
symptoms has impeded clinical advancements in the most
commonly affected patient population, advanced metastatic
cancer patients.5,7,9–11 Our results demonstrate that the
VM-M3 model replicates the progressive and spontaneous
nature of metastatic disease which facilitates the development of the full clinical CACS environment via progressive
wasting of skeletal muscle with observed alterations in IGF1/insulin, FOXO3a, and ubiquitin proteasome degradation
pathway, along with adipose tissue wasting, systemic inﬂammation, anorexia, anemia, hypoalbuminemia, elevated protein breakdown, and metabolic derangement with sexspeciﬁc discrepancies. Additionally, our work demonstrates
that the administration of a non-toxic KDE added to a standard diet was well tolerated, shifted systemic metabolism,
mitigated comorbid symptoms, attenuated tumor burden indices, and reduced catabolism in both the progressive metastatic CACS and cancer-independent septic/inﬂammatory
atrophy environments. These results illustrate that the KDE
is a unique, novel, and multifaceted anti-CACS therapeutic
with direct anti-catabolic effects in atrophy environments.
The VM-M3 model presents a unique metastatic model in
which subcutaneously implanted VM-M3 luciferaseexpressing cells can develop a primary tumor, spontaneously
leave the primary tumor site, enter the circulation, and
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produce distant metastases that can be monitored by bioluminescence imaging. Intraperitoneal implantation of VM-M3
cells also induced similar systemic metastases, progressive tumor burden, and CACS phenotype to subcutaneous implantation illustrating a consistent modeling system (Table S2). This
is distinct from other models which require intravenous implantation or the assistance of surgical resection of the primary tumor to induce metastases.7 The reliable,
reproducible, and logistically feasible nature of this metastatic model13,14 may present numerous experimental advantages over emergent genetically engineered modeling
systems which often require lengthy and costly experimental
designs due to heterogeneous tumor onset and growth, metastatic progression, and cachexia occurrence. Additionally,
metastases can directly disrupt cancer-burdened tissue and
indirectly disrupt noncancerous tissue through secretory factors or alterations in host-tissue response,12 further highlighting the need to model the complex metastatic CACS.
Among the hallmark characteristics of cachexia is the atrophy of skeletal muscle and often adipose tissue,1–3 with
bodyweight being most commonly used clinically as a surrogate marker for both due to ease of assessment. It is important to note, however, that tissues can atrophy and/or
hypertrophy in an asymmetric manner, highlighted in cancer
patients with sarcopenia obesity and in cachexia trials using
appetite stimulants, where it has been reported that adipose
tissue can increase while skeletal muscle progressively atrophies.33–35 Similarly, we demonstrated the nonspeciﬁcity of
bodyweight as a determinant for cachexia status, while tissue
speciﬁc assessment of wasting did reveal progressive skeletal
muscle wasting, the hallmark characteristic of cachexia.1–3 Interestingly, while hind limb weights atrophied in a progressive manner, we did not observe decreases in quadriceps
tissue until after Week 3. This preferential retention in
quadricep muscle mass over gastrocnemius and soleus has
also been reported in the C26 cachexia rodent model36 and
in patients with disuse atrophy.37 This may be explained by
gene expression differences across muscle groups72 as epigenetic modulation of gene expression has been shown to regulate wasting in cachexia, disuse atrophy, and nutrient
deprivation.67,73 While we observed quadricep atrophy
across sexes, sex-speciﬁc quadricep wasting has been previously reported,38 highlighting a reported need for further
sex-speciﬁc analysis in clinical cohorts.74 While skeletal muscle wasting is central to the disease, adipose tissue wasting
has gained considerable attention, as recent reports have
demonstrated that adipose tissue wasting may regulate skeletal muscle wasting in several cachexia models.75 We demonstrate that VM-M3 males had progressive adipose tissue
wasting, while VM-M3 females demonstrated sex-speciﬁc retention of adipose tissue until after Week 3. Previous reports
conﬁrm differential degree and timing of tissue wasting39,40
and function76 between males and females, hypothesized76
or explained by hormonal differences.39
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While metastasis and tissue wasting are important components of CACS, accompanying systemic inﬂammation, anorexia,
anemia,
elevated
protein
breakdown,
hypoalbuminemia, and metabolic derangement demonstrate
the full multifactorial CACS.1–3,9–11,43,46–50 Inﬂammation has
been commonly reported to play roles in multiple aspects
of the CACS wasting scenario including tissue wasting, anorexia, metabolic abnormalities, tumor progression, among
others.3,43 We observed progressive systemic inﬂammation
across metrics of spleen enlargement, white blood cell elevation, and augmented pro-inﬂammatory cytokines. Anorexia is
a common, contributory, and clinically impactful side effect of
CACS.2,10,11 Both cachexia and anorexia can be mechanistically driven by a pro-inﬂammatory state,43 which were simultaneously observed in the VM-M3 model. Finally, we
demonstrated that the VM-M3 model had the comprehensive clinical biomarkers observed in cachexia patients that
are often unevaluated in rodent model systems, including
anemia, metrics of protein breakdown, hypoalbuminemia,
and metabolic derangement. This is salient as many mechanisms and therapeutic strategies proposed for CACS are
largely dependent on modeling systems known to not recapitulate or remain unevaluated for the full CACS.
Multiple driving mechanisms of skeletal muscle atrophy
have been proposed and explored for cachexia,3 yet limited
patient data lead to many unanswered questions related to
the underlying drivers at the skeletal muscle level.6 However,
emerging evidence from rodent models indicates that the
ubiquitin proteasome degradation pathway is a prominent
contributor to skeletal muscle atrophy.3,56,57 We observed elevated serum TNF-α and skeletal muscle protein polyubiquitination, without alterations in acute or chronic
markers suggestive of NF-κB activation which could be explained by an observed elevation in IL-10 serum levels.65
We did, however, note signiﬁcantly reduced serum IGF-1
and insulin levels along with elevated nuclear FOXO3a levels
in skeletal muscle; the latter being an established upstream
modulator of the ubiquitin proteasome pathway.56,66 Importantly, IGF-1/insulin signaling has an established role in muscle homeostasis and alterations in pathway modulators
and/or signaling components have been observed in patients
across multiple atrophy environments including cachexia, nutrient deprivation/anorexia, sepsis, diabetes, sarcopenia,
amongst others, demonstrating a clinically relevant mechanism in atrophy-based disease.3,56,57
While the VM-M3 model serves as a robust and comprehensive modeling system for CACS, there is currently no effective treatment for this multifaceted disease. KDE is a
non-toxic synthetic exogenous ketone compound composed
of a R/S 1,3-butanediol backbone esteriﬁed to two
acetoacetates. Upon oral administration, KDE increases circulating levels of the ketone bodies β-hydroxybutyrate and
acetoacetate, while decreasing blood glucose in a dosedependent manner without the barriers of whole
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lifestyle/dietary changes or IV infusion.77,78 We observed elevations in circulating ketone bodies and decreases in blood
glucose in a dose-dependent manner when administered
chronically via food and acutely via oral gavage in the context
of a standard diet. This presents a major step toward the clinical advancement of ketone therapeutics as fasting-induced
ketone elevations and glucose reductions in cachexia patients
are contraindicated, due to a fear that nutrient deprivation
will exacerbate tissue atrophy. While the very low carbohydrate ketogenic diet has overlapping metabolic effects and
circumvents nutrient deprivation, major dietary modiﬁcations
are difﬁcult for some patients to sustain,79 and compliance
can be further complicated by disease. Moreover, while direct IV infusion of metabolites into circulation allows for
dose-dependent elevations in circulating ketone bodies without altering diet, this is limited to the clinical or research environment. Thus, KDE provides an orally consumable and
well-tolerated method for modulating systemic metabolism
without dietary restriction or direct circulatory infusion.
Tumor burden and metastatic spread directly impact cachexia risk and progression. Prior work has demonstrated
that a very low carbohydrate ketogenic diet can attenuate
cancer burden across various preclinical cancer models.23,80
Ketone bodies have also been demonstrated to induce direct
anticancer effects which have been proposed to occur via alterations in energetic metabolism, oxidative stress, inﬂammation, and/or epigenetic regulation.14,23,80,81 Here we
demonstrate that chronic KDE administration in the context
of a standard diet mitigated indices of tumor burden. Interestingly, while we would expect caloric restriction to induce
an antitumor response, KDE antitumor response was present
even though comorbid anorexia (involuntary caloric restriction) was mitigated in the KDE group. Seemingly contrary to
the KDE anti-anorexic effects presented here are the
ketone-induced reduction in food intake previously reported.68,69 This was achieved through the alteration of standard diet palatability and a stepwise integration of KDE to
mitigate this confounder in non-diseased animals. Additionally, we demonstrated that the KDE mitigated anorexia in
both the CACS and LPS/septic anorexic environments. Given
the established role of inﬂammation in anorexia43 and the reported anti-inﬂammatory effects of KDE,25,26 it is possible
that ketones may mitigate anorexia via alterations in systemic
inﬂammation in both CACS and LPS/sepsis.
Atrophy/catabolism is the hallmark characteristic of CACS,
and ketone bodies have been shown to be associated with or
directly reduce metrics of protein breakdown across various
populations following nutrient deprivation,15,16 acute IV infusion16–18 or through in vitro analysis.20,21 However, the
chronic effects of ketone bodies on the principle outcome,
atrophy/catabolism, have not been determined, nor has the
efﬁcacy of orally administered exogenous ketone bodies been
tested across various multifaceted atrophy environments.
Here we demonstrate that administration of oral exogenous
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ketone bodies mitigated catabolism in two multifactorial and
overlapping inﬂammatory environments. First, KDE attenuated muscle atrophy in CACS without altered input from upstream anabolic hormones deemed mechanistically involved
in tissue wasting. Second, KDE mitigated LPS/sepsis catabolism even when controlling for comorbid food
intake/anorexia. Mechanistically, patients exhibited reduced
IGF-1/insulin, stably decreased glucose, and increased ketone
bodies during prolonged fasting-induced atrophy.15,16 These
studies also uncovered that as ketone bodies become elevated, metrics of protein breakdown progressively decreased
along with a threefold to sixfold reduction in amino acid efﬂux from skeletal muscle, suggesting a direct ketone-induced
effect on protein turnover. Additionally, recent work in patients with LPS/sepsis demonstrated that direct IV infusion
of ketone bodies induced a potent acute anti-catabolic response in the skeletal muscle, even when controlling for the
potential confounding effects of GPR109a (HCAR2) signaling
on NF-κB.17,27 Importantly, fasting,15,66 LPS/sepsis,82 and
CACS3,83 have all been shown to reduce IGF-1/insulin signaling. This overlapping atrophy signaling in our work and others
indicating that ketone bodies attenuate catabolism in all
three conditions,15–17 even when controlling for confounding
GPR109a/NF-κB signaling and circulating IGF-1/insulin levels,
suggests other possible mechanisms. Ketone-induced histone
acetylation via Classes I and II histone deacetylase (HDAC) inhibition is one possible anti-catabolic mechanism as (a) Classes I and II HDAC-induced atrophy occurs across multiple
catabolic states67,84,85; (b) inhibition of Classes I and II HDACs
and the subsequent histone acetylation in skeletal muscle is
sufﬁcient to inhibit skeletal muscle atrophy via the restriction
of FOXO3a nuclear accumulation67; (c) genetic deletion of
HDAC4 attenuates activations of ubiquitin proteasome degradation in multiple models of atrophy86,87; (d) ketone bodies
inhibit Classes I and II HDACs and promote histone acetylation in many tissues,88 including skeletal muscle22; (e) ketone
bodies elicit anti-atrophy effects across multiple catabolic environments.15–17,20,21,27 However, there is also evidence that
FOXO3a levels increase with diet-induced ketone elevations.22,88 Still, neither analysis indicated FOXO3a skeletal
muscle nuclear localization. Additionally, FOXO3a has consistently been shown to induce atrophy in skeletal muscle,
which contradicts work demonstrating the anti-atrophy effect
of ketone bodies in environments where IGF-1/insulin signaling is commonly suppressed.15–17 However, ketone bodies
have been demonstrated to have other anti-catabolic mechanisms which cannot be ruled out in the present analysis.27
Thus, KDE-induced inhibition of Classes I and II HDAC, the
subsequent histone acetylation, and efﬂux of nuclear
FOXO3a, along with regulatory capacity across catabolic, synthetic, and metabolic pathways, present potential antiatrophy mechanism(s) which should be examined in future
analysis. Additionally, while STAT3- and autophagy-induced
atrophy signaling remain unexplored in the current analysis,

the observed elevations in serum IL-6 and skeletal muscle
FOXO3a nuclear localization indicates that we cannot exclude
these potentially contributory pathways.
While our work and others suggest ketone bodies have a
pluripotent therapeutic role in wasting environments, the
ability of the KDE to induce these effects without altering circulating anabolic hormones may have important clinical relevance. First, various attempts to inhibit FOXO3a and ubiquitin
proteasome degradation in the inﬂammatory environment
via elevations in anabolic hormones have not proven efﬁcacious.82,89 This is likely due to skeletal muscle resistance to
IGF-1/insulin signaling in these inﬂammatory environments.47,90–92 While inﬂammation-induced IGF-1/insulin resistance is not fully understood, multiple reports indicate
this may be occurring at the receptor level.90,91 Interestingly,
our work demonstrated an anti-catabolic effect of ketone
bodies across low IGF-1/insulin signaling and proinﬂammatory environments demonstrating that ketones
may present a modulatory tool for this catabolic pathway
by circumventing previous therapeutic resistance. Secondly,
discussion has emerged around the proposed dichotomy of
IGF-1 on skeletal muscle mass, cancer growth, and metastasis,93 and longevity.57 Thus, ketone bodies’ ability to promote
optimal muscle mass while mitigating perceived risk for adverse health or disease outcomes is a ﬁnding worth future
clinical exploration. Beyond tissue atrophy/catabolism, ketone bodies have been demonstrated to directly regulate metabolism, reduce oxidative stress, attenuate inﬂammation,
and regulate epigenetics, amongst other effects.23–26 Consequently, ketone bodies may help support improved patient
outcomes across various multifaceted diseases including cancer, CACS, sepsis, amongst others, where atrophy/catabolism
is only one component compromising patient outcomes.
Taken together, this work demonstrates a comprehensive,
metastatic, and progressive model of CACS with sex-speciﬁc
variation, and a non-toxic exogenous ketone therapy with
metabolic, anti-catabolic, anti-anorexic, and antitumor therapeutic effects across various multifaceted atrophy/catabolic
environments. Future studies are warranted to further investigate other mechanisms through which the KDE attenuates
atrophy and comorbidities, determine optimal KDE administration protocol, evaluate potential synergistic therapeutic
strategies to optimize therapeutic effect, and most notably,
determine whether KDE can be a supportive nutritional therapeutic in clinical CACS and inﬂammatory atrophy
environments.
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Data S1. Supporting information
Table S1. Experimental Design Experimental Design reference
table for main experiments. Data information: Abbreviations:
R βHB, R β-Hydroxybutyrate; SH-M, Sham Males; CA-M, Cancer Males; SH-F, Sham Females; CA-F, Cancer Females; EOL,
End of Life; VM-M3, VM-M3 Mouse Model of Systemic
Metastasis; KDE, Ketone Diester; LPS, Lipopolysaccharide/Endotoxin. *= One unexplained animal death immediately postinoculation.
Table S2. VM-M3 Subcutaneous Versus Intraperitoneal
Implantation. Overlapping phenotype observed with 1×106
VM-M3 subcutaneous and intraperitoneal implantation. Data
information: Abbreviations: CA-M, Cancer Males; SH-M,
Sham Males. Red line indicates region of interest (ROI). Color
Scaling: Radiance (photons/sec/cm2/sr).
Table S3. Ketone Diester Physical Properties Physical
properties reference table for R/S 1,3-Butanediol
Acetoacetate Diester. Data information: Abbreviations: GC/
MS, Gas Chromatography Mass Spectrum Analysis.
Table S4. Ketone Diester Preparation and Analysis. Preparation and conﬁrmation analysis for R/S 1,3-Butanediol
Acetoacetate Diester chemical synthesis. Data information:
Abbreviations: GRAS, Food and Drug Administration Generally Recognized as Safe; GC-FID, Gas Chromatography
Flame-Ionization Detection.
Figure S1. Baseline Sex, Bodyweight, and Age Controlled with
Similar Survival in Males and Females. A Sham Males (SH-M),
Cancer Males (CA-M), Sham Females (SH-F), Cancer Females
(CA-F) bodyweight (SH-M, n=20; CA-M, n=20; SH-F, n=18;
CA-F, n=18), age (SH-M, n=20; CA-M, n=20; SH-F, n=18; CAF, n=18), and daily food intake (SH-M, n=12; CA-M, n=12;
SH-F, n=11; CA-F, n=12) were matched at baseline. Data:
Bodyweight and Age, Experiment 1a&b; Food Intake, Experiment 1a. B Sham Males (SH-M) week 1 (n=4), SH-M week 2
(n=4), SH-M week 3 (n=5), Cancer Males (CA-M) week 1
(n=4), CA-M week 2 (n=4), CA-M week 3 (n=5), SH-F week 1
(n=5), SH-F week 2 (n=5), and SH-F week 3 (n=6), Cancer Females (CA-F) week 1 (n=5), CA-F week 2 (n=5), CA-F week 3
(n=6) were similar in bodyweight and age, although females
tended to smaller. No signiﬁcant differences in food intake
were observed between CA-F or SH-F except between SH-F
week 3 and CA-F week 3. Differences were observed across
male groups and CA-F week 2 & 3. Data: Experiment 2. C
Mean Survival for CA-M (n=20, 31.3 days) and CA-F (n=18,
32.3 days). Data: EOL, Experiment 1a&b. Data information:
Differences across groups at each timepoint were analyzed
with One-Way ANOVA with Tukey’s post-hoc (A,B).
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Differences across groups were analyzed with unpaired t-test
(C). Data are mean ± SEM. nsP>0.05, *P<0.05, **P<0.01,
****P<0.0001.
Figure S2. VM-M3 Develop Prolonged Systemic Inﬂammation.
A Liver weights as a ratio baseline bodyweight for Sham
Males (SH-M), Cancer Males (CA-M) (M week 1, n=4; week
2, n=4; week 3, n=5; end of life, EOL, n=20), Sham Females
(SH-F), and Cancer Females (CA-F) (F week 1, n=5; week 2,
n=5; week 3, n=6; EOL, n=17). Data: Week 1-3, Experiment
2; EOL, Experiment 1a&b. B Cytokines quantiﬁcation via
Luminex ﬂuorophore intensity analysis (n=8-12/group/
timepoint). Data: Week 1-3, Experiment 2; EOL, Experiment
1a. Data information: Within group differences across time
were analyzed with One-Way ANOVA with Tukey’s posthoc
with >3 comparisons (A) and Fischer LSD post-hoc for ≤3
comparisons (B). Differences across groups at each timepoint
were analyzed with unpaired t-test. (A,B) Prior to ANOVA cytokine analysis, robust regression and outlier removal (ROUT)
with coefﬁcient Q=1% was used as non-physiologic/error
values were detected (B). Abbreviations: IP-10, IFN-γ-Inducible Protein 10; KC, Keratinocyte-Derived Cytokine; MIG,
Monokine Induced by IFN-γ. Colors (A-B): CA-M, Blue; CA-F,
Red. Data are mean ± SEM. *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001.
Figure S3. VM-M3 Circulating Lipids. A Total Cholesterol (n=5/
group), Triglycerides (n=4/group) and Lipase (n=5/group)
were analyzed via colorimetry analysis. Data: EOL, Experiment
1a. Data information: Across sex differences were analyzed
with unpaired t-test. Abbreviations: SH-M, Sham Males; CAM, Cancer Males; SH-F, Sham Females; CA-F, Cancer Females.
Data are mean ± SEM. *P<0.05.
Figure S4. Alterations Seen in VM-M3 Cannot Be Explained by
Altered Hydration Status A Organic Phosphorous (males n=5/
group; female n=4/group), Calcium (males n=5/group; female
n=4/group), Sodium (n=3/group), Potassium (males n=3/
group; female n=4/group), Chloride (males n=2-3/group; female n=4/group), Magnesium (males n=3/group; female
n=4/group) were quantiﬁed via potentiometrics. Data: EOL,
Experiment 1a. Data information: Across sex differences were
analyzed with unpaired t-test. Abbreviations: SH-M, Sham
Males; CA-M, Cancer Males; SH-F, Sham Females; CA-F, Cancer Females. Data are mean ± SEM. **P<0.01.
Figure S5. Serum and Skeletal Muscle Molecular Dynamics
RT-qPCR analysis of mRNA GPR109a in Sham Males (SH-M)
and Cancer Males (CA-M) revealed no differences (n=12/
group). Data: Gastrocnemius, EOL, Experiment 1a. B Total
RNA was quantiﬁed via UV Spectroscopy and was signiﬁcantly
reduced in CA-M compared to SH-M (n=12). Data: Gastrocnemius, EOL, Experiment 1a. C BCA colorimetric assay indicated
Nuclear Fraction Total Protein was signiﬁcantly reduced in
CA-M (n=10) compared to SH-M (n=12). Data:

993

Gastrocnemius, EOL, Experiment 1a. D Immunoblotting
Ubiquitination and Ponceau Staining. Data: Gastrocnemius,
EOL, Experiment 1a. E Immunoblotting 20S Proteasome Core
(30 kDa) and Ponceau Staining. Data: Gastrocnemius, EOL, Experiment 1a. F Immunoblotting Total NF-κB (65 kDa) and
Ponceau Staining. Data: Gastrocnemius, EOL, Experiment 1a.
G Immunoblotting Cytosolic and Nuclear OGG1 conﬁrming
nuclear fractionation. Immunoblotting Nuclear Fraction Total
NF-κB (65 kDa) and FOXO3a (73kDa), and Ponceau Staining.
SH-M10 not analyzed due to tissue limitation. Data: Gastrocnemius, EOL, Experiment 1a. H Immunoblotting MuRF-1 (43
kDa) and Ponceau Staining. Data: Gastrocnemius, EOL, Experiment 1a. I Immunoblotting Atrogin-1 (40 kDa) and Ponceau
Staining. Data: Gastrocnemius, EOL, Experiment 1a. Data information: Within group differences across time were analyzed with One-Way ANOVA with Fischer LSD post-hoc for
≤3 comparisons (A). Differences across groups at each
timepoint were analyzed with unpaired t-test (AD). Prior to
ANOVA cytokine analysis, robust regression and outlier removal (ROUT) with coefﬁcient Q=1% was used as non-physiologic/error values were detected (A). Abbreviations: OGG1, 8Oxoguanine-DNA Glycosylase 1. Data are mean ± SEM.
ns
P>0.05, *P<0.05, ***P<0.001.
Figure S6. Ketone Diester Food Incorporation Alters Systemic
Metabolism and is Well Tolerated. A Baseline food intake,
bodyweight, and age (n=12/group). Data: Experiment 4c. B
Bodyweight tracked daily with step-wise increase in KDE indicating tolerability of 30%KDE incorporated with highly palatable standard diet (HPSD) (n=4). Data: Experiment 4b. C
Blood Glucose and Ketones were quantiﬁed via enzyme interaction for animals fed 20% (n=5), 25% (n=3), 30% (n=5) Ketone Diester (KDE) on top of standard diet. 30%KDE induced
largest alterations in systemic metabolism. Data: Experiment
4a. Data information: Across group differences were analyzed
with One-Way ANOVA with Fischer LSD post-hoc for ≤3 comparisons (A, C). Differences within groups (C) at each
timepoint were analyzed with unpaired t-test. Differences
compared to Day 0 were compared with One-Way ANOVA
with Dunnett post hoc (B). Colors (C): Post-KDE, Green. Data
are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
Figure S7. Bodyweights Were Controlled Prior to LPS Experimentation. A Baseline bodyweight for animals prior to administration of 10mg/kg lipopolysaccharide with either 4mL
water (LPS, n=4) or 4mL/kg KDE (KDE+LPS, n=5) gavage. Data:
Experiment 5b. B Baseline bodyweight for animals prior to
administration of 10mg/kg lipopolysaccharide with LPS (n=4)
or KDE+LPS (n=4) gavage and pair-feeding. Data: Experiment
5c. Data information: Difference across groups were analyzed
with unpaired t-test for individual comparisons (A-B). Data
are mean ± SEM. nsP>0.05.
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